Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

Verona Pharma is looking odds on for a regulatory approval for its chronic obstructive pulmonary disease (COPD) therapy ensifentrine, after chalking up a second positive phase 3 trial. The Anglo ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

The Anglo-American biotech is already developing ensifentrine in chronic obstructive pulmonary disease (COPD), but the company believes it could also help to relieve respiratory symptoms ...

Both dupilumab and ensifentrine, a phosphodiesterase (PDE) 3 and PDE4 inhibitor also recently approved for maintenance treatment of COPD, have been shown in clinical trials to reduce exacerbations ...

This study documents that anemia occurs relatively frequently in COPD patients and is related to the presence of inflammation. Anemia is an understudied issue in COPD but may be of great ...

(RTTNews) - 2024 has been a banner year for Verona Pharma (VRNA), with its share price surging more than threefold in just 7.5 months. The ...

Consensus for Q4 revenue is $12.94M. Expects to report cash and cash equivalents at December 31, 2024, of $400M vs. $271.8M a year ago. “2024 ...

Ensifentrine (Ohtuvayre) acts as bronchodilator and non-steroidal anti-inflammatory agent. It is formulated as suspension for inhalational route of administration. Ohtuvayre is indicated for the ...

Discover the top 19 most notable drugs approved by the FDA in 2024, including Dupixent for COPD and FluMist for self-administration. See the full list here.